Clinical Trials Browser

Phase 1/2 × OTHER × Paraproteinemias × Clear all

Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Hemostatic Disorders, Neoplasms, Plasma Cell

NCT05573802 2023-10-24

A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma

Phase 1/2 Recruiting

36 enrolled

Plasma cell

Blood Protein Disorders, Corneal Diseases, Hematologic Diseases, Multiple Myeloma, Neoplasms, Paraproteinemias, Neoplasms, Plasma Cell

NCT05581875 2022-10-17

A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory

Phase 1/2 Not yet recruiting

48 enrolled

Plasma cell

Blood Protein Disorders, Corneal Diseases, Hematologic Diseases, Multiple Myeloma, Neoplasms, Paraproteinemias, Neoplasms, Plasma Cell

NCT00048412 2020-01-18

Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H

Phase 1/2 Completed

40 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoproliferative Disorders, Multiple Myeloma, Paraproteinemias

NCT00579111 2016-05-04

Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB)

Phase 1/2 Terminated

4 enrolled 8 charts

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hematologic Diseases, Lymphoproliferative Disorders, Multiple Myeloma, Myeloproliferative Disorders, Paraproteinemias, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Clinical Trials

BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple Myeloma

A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma

A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory

Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H

Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB)